Home
/ NKMax

NKMax

NKMax

Total Funding

$11 M

NKMax Summary

Company summary

Overview: NKMax America is a company developing cellular therapies that use the power of a patient’s immune system. It helps people with cancer, autoimmune disease, and neurodegeneration.

Type: Private

Status: Active

Founded: 2017

HQ: Santa Ana, CA, US | view all locations

Website: https://nkgenbiotech.com/

Cybersecurity rating

Sectors

LocationsView all

1 location detected

Santa Ana, CA HQ
United States
3001 Daimler St

Competitors and similar companies

Compare competitors

News

NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Oct 4, 2021

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

Apr 13, 2021

NKMax America Announces Corporate Name Change to NKGen Biotech

Apr 2, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Mar 31, 2021

Footer menu

Products

Solutions

Resources

Company

© Craft.co 2023

Share price data provided by IEX

Company directory

Search directory